Global stock markets rebound on upbeat speech from Fed boss Janet Yellen as analysts pencil in Christmas rate rise This is Money – 25 Sept http://www.thisismoney.co.uk/money/markets/article-3248751/Global-stock-markets-rebound-upbeat-speech-Fed-boss-Janet-Yellen-analysts-pencil-Christmas-rate-rise.html London’s UK 100 soars on hopes of higher US interest rates Standard – 25 Sept http://www.standard.co.uk/business/londons-UK Index -100-soars-on-hopes-of-higher-us-interest-rates-a2955602.html European stocks motor ahead at open AFP – 25 Sept http://www.afp.com/en/news/european-stocks-motor-ahead-open…
24 September 2015 Shares in BMW (BWM) are weak again today on speculation that its diesel emissions test results may also have been doctored to appear eco-friendly and thus saleable in the world’s second largest but arguably the most important car market; the US. While this adds to this week’s VWgate revelation, confirmation of yet…
23 September 2015 Diversified engineer and perennial break-up target/candidate Smiths Group (SMIN) is the UK Index ’s top beneficiary of stock-specific news this morning. Traders have pushed the shares off 2015 lows after FY15 results showed profits +5.6% in the face of revenues -1.7% as business conditions remained tough due to lower oil process and…
22 September, 2015 RSA Insurance (RSA) may have been jilted at the M&A alter by Swiss heavyweight Zurich Financial (ZURN), but soothing comments from CEO and ex-RBS boss Stephen Hester (summer trading above expectations) are doing the job of convincing investors that there is nothing wrong and that it ‘wasn’t us it was them’. With…
It’s a bit like the Tour de France. Volkswagen, the German carmaker (for those of you who are in your infancy or were never born), has both been accused of and freely admitted to a mammoth program of doping…sorry, emissions tests circumvention that’s put it in front of a potential $18bn fine courtesy of the…
21 September, 2015 Shares in Shire (SHP) are the wining the race to the top of the UK Index this morning as investors cheer news that its Intuniv drug has been awarded European approval for use as a non-stimulant drug for Attention Deficit Hyperactivity Disorder (ADHD) in children and adolescents (6-17yrs old ) from whom…